When the laughter of children fades from school campuses in Selangor, when long queues form outside clinics in Penang, and when 6,000 students are forced to quarantine at home due to influenza, Malaysia is facing another public health challenge in the post-COVID-19 era. This large-scale outbreak of Class A influenza sweeping across 14 states and territories in the country has turned "fever and cough" into non-trivial symptoms, making every family urgently need a reliable health defense line. In such a special period, we understand that a fast and accurate test report is not only a responsibility to one’s own health but also a protection for family members, neighbors, and the entire community.
Data from Malaysia’s Ministry of Health shows that the number of clustered influenza cases has surged nearly 7 times compared to the previous week, with schools and kindergartens being the hardest-hit areas. More worrying is that the spread of respiratory viruses often features "co-infection" — when the influenza virus interacts with multiple pathogens such as COVID-19, RSV (Respiratory Syncytial Virus), and ADV (Adenovirus), it not only increases the difficulty of diagnosis but also poses life-threatening risks to vulnerable groups like children, the elderly, and patients with chronic diseases. Datuk Dr. Tirunavukarasu, President of the Malaysian Medical Association, specifically warned: "Early testing allows patients to receive treatment faster, thereby reducing the risk of complications." However, traditional single-target testing methods often struggle to cope with the complex situation of viral infections. How to accurately identify pathogens in the shortest time has become a key to current epidemic prevention and control.
In response to such public needs, we have launched the COVID-19/RSV/ADV/Flu A&B Antigen Combo Rapid Test Kit, committed to providing Malaysians with a "one test, multiple protections" solution. This test product, certified by Malaysia’s Medical Device Authority (MDA), not only retains the advantages of colloidal gold technology — speed and convenience — but also innovatively integrates the detection of five common respiratory pathogens into a single kit, perfectly meeting the needs of current complex epidemic prevention and control.
For every anxious family, "speed" means hope. Our test kit achieves a breakthrough of delivering results within 15 minutes. No professional laboratory or complex equipment is required; the entire testing process can be completed at home. Imagine: when a child suddenly has a fever, there is no need to travel to and from the hospital (risking cross-infection). With just a few simple steps, accurate results can be obtained in the time it takes to finish a meal. This not only saves parents precious time but also secures an opportunity for the child to receive timely treatment. As a pediatrician in Kuala Lumpur put it: "During the peak influenza season, reducing unnecessary hospital visits is itself an effective prevention and control measure."
"Accuracy," on the other hand, is the lifeline of testing. Our product adopts high-sensitivity antigen detection technology, with a detection rate of over 98% for Flu A and B, while effectively distinguishing between other respiratory viruses such as COVID-19, RSV, and ADV. This "5-in-1" detection capability completely solves the problems of missed diagnosis and misdiagnosis that may occur with traditional single-target tests. Especially in the current context where influenza and COVID-19 cases coexist, a single test can identify the cause of illness, avoiding the troubles of "blind medication" and "repeated testing," and making treatment more precise and efficient. For high-risk groups such as the elderly in nursing homes and children with asthma, such accurate testing serves as a crucial barrier to safeguarding their lives.
At the public health level, this flu RSV combo test kit also provides strong support for community prevention and control. Malaysia’s Ministry of Education requires schools to "abide by the prevention and control guidelines implemented during the COVID-19 epidemic," and our product is the perfect implementation of this requirement: schools can use it as an important tool for back-to-school screening; enterprises can apply it to employee health monitoring; and primary medical institutions can build a three-level joint prevention and control system of "preliminary screening - confirmation - referral" through rapid testing, effectively alleviating the pressure of strained medical resources. As Kangxin Consulting emphasized when assisting in medical device registration, high-quality IVD (In Vitro Diagnostic) products should "empower primary healthcare and solve the difficulties of 'inability to test, inaccurate testing, and slow testing'."
We are well aware that every test kit is connected to the concerns of a family. Therefore, in product design, we have placed special emphasis on ease of operation and user-friendliness: the clear instruction manual is illustrated with pictures and text, making it easy for even the elderly to master; the sampling process is gentle and painless, so children no longer resist testing; the independently packaged test cards are not only easy to carry but also effectively prevent cross-contamination. We hope that this product is not just a medical testing tool, but also a link for conveying care, allowing every Malaysian family to face viruses with more calmness and less panic.
Currently, Malaysia’s Ministry of Health is still promoting the influenza vaccination program in phases. However, the temporary shortage of vaccine supplies has made testing and protection even more important. In this special season, we call on every family to prepare for "early testing, early quarantine, and early treatment," and use scientific protection to safeguard the health of themselves and their families. Our combo test kit is now available in major pharmacies and online platforms across the country, providing Malaysians with accessible health protection.
The influenza epidemic will eventually pass, but the responsibility of safeguarding health will never be relaxed. We have always believed that the true responsibility of an enterprise lies not only in providing high-quality products but also in overcoming difficulties together with society. In this battle without smoke, we are willing to stand side by side with the Malaysian government, medical institutions, and every family, using technological innovation to build an indestructible health defense line. We aim to restore vitality to campuses at an early date and return life to its beautiful and peaceful state. Because we deeply understand that safeguarding the health of every individual is safeguarding Malaysia’s future.
Symptom Recognition
The disease onset is sudden, accompanied by high fever (39-40℃), chills, headache, muscle aches, and other systemic symptoms. Some patients may experience sore throat, cough, or gastrointestinal symptoms.
It is necessary to distinguish it from the common cold. If high fever persists for more than 3 days, difficulty breathing occurs, or other severe symptoms appear, high-risk groups must seek medical attention immediately.
Treatment and Care
Within 48 hours of the onset of symptoms, take anti-influenza virus drugs (such as oseltamivir) as prescribed by a doctor; do not use antibiotics blindly.
Quarantine at home and rest, drink plenty of warm water. For high fever, use physical cooling methods or antipyretics/analgesics, and keep the room well-ventilated.
Prevention Measures
Get an influenza vaccine every year from September to November.
Wash hands frequently (rub for at least 20 seconds). During the influenza season, avoid crowded places and wear a mask when going out.
Cover the mouth and nose with a tissue, towel, etc., when coughing or sneezing to prevent droplet transmission.
Use personal items (tableware, towels, etc.) separately and disinfect them regularly.
Ventilate the room 2-3 times a day, for more than 30 minutes each time.
Maintain a regular schedule, a balanced diet, and moderate exercise to enhance immunity; avoid overwork, which may reduce resistance.
Special Groups
The elderly, children, pregnant women, and patients with chronic diseases should be prioritized for vaccination. Family members should pay extra attention to them and seek medical attention promptly if they are infected.
Recently, Malaysia has been hit by the most severe respiratory virus transmission event since the COVID-19 pandemic. The influenza A (Flu A) epidemic is spreading rapidly across 14 states and federal territories in the country, with Selangor becoming the "hardest-hit area by the virus." Nearly 100 clustered influenza cases have been reported one after another. The Ministry of Education has urgently ordered school closures in many areas, some lasting up to a week, and approximately 6,000 students have been forced to quarantine at home for observation. More critically, this epidemic is not caused by a single virus — COVID-19, Respiratory Syncytial Virus (RSV), Adenovirus (ADV), and influenza A&B viruses have formed a "mixed viral army," posing enormous challenges to clinical diagnosis and prevention work.
Dilemmas in Multi-Virus Prevention and Control
Monitoring data from Malaysia’s health authorities shows that although the positive rate of influenza samples has dropped from 26.1% in the 1st epidemiological week of 2025 to 21.97% in the 4th week, clustered infections in densely populated places such as schools and communities continue to rise. This seemingly contradictory phenomenon stems from the overlapping prevalence of multiple respiratory viruses — clinically, symptoms such as fever, cough, nasal congestion, and runny nose are highly similar among COVID-19, influenza, RSV, and ADV infections, making it difficult to distinguish them based solely on symptoms.
Children and the elderly have become the high-risk groups in this epidemic. Among patients admitted to Malaysian hospitals, there are infants under 2 years old with wheezing symptoms caused by RSV infection, school-age children with high fever and muscle aches caused by influenza A, and some immunocompromised elderly people showing signs of co-infection. This multi-virus prevalence situation not only leaves patients confused about "which virus they are infected with" but also puts medical institutions in a dilemma of low diagnostic efficiency and difficult resource allocation.
The Problem-Solving Value of 5-in-1 Test Kits
Facing the complex epidemic situation, the emergence of the COVID-19/RSV/ADV/Flu A&B Antigen Combo Rapid Test Kit has provided a precise and efficient solution for virus prevention and control in Malaysia. Its core value is reflected in three key dimensions:
1. Multi-Target Detection in One Card, Solving the Dilemma of Differentiation
Using colloidal gold immunochromatography technology, this test kit can simultaneously detect antigens of COVID-19, RSV, ADV, and influenza A&B viruses in nasopharyngeal swab samples, delivering clear results within 15-30 minutes. For patients with fever symptoms, there is no need for multiple samplings or multiple test kits — a single operation can identify the infectious pathogen, completely addressing the diagnostic pain point of "similar symptoms, difficult to distinguish."
In scenarios with clustered epidemics (such as schools), this multi-target detection capability is particularly important. Medical staff can quickly screen out influenza-infected patients and those infected with other viruses, enabling classified quarantine and precise handling, and avoiding the risk of epidemic spread caused by misdiagnosis.
2. Easy to Use, Enable Human to Screening Their Health Status Anywhere, Anytime
Considering the uneven distribution of primary medical resources in Malaysia, the test kit adopts a non-invasive sampling design, equipped with dedicated swabs and lysis buffer. No professional testing equipment is required; even primary medical staff or trained school health workers can operate it independently. Rapid testing can be carried out in hospital fever clinics, community health centers, temporary quarantine sites, and school infirmaries.
This adaptability is consistent with respiratory virus test products launched by Chinese enterprises and approved in Malaysia previously. For example, combined test kits from companies like Innodx have obtained qualification certification in Malaysia, and their convenience has been recognized by the local market — laying a foundation for the launch of this 5-in-1 test kit.
3. Early Diagnosis and Treatment, Reducing Prevention and Control Costs
The value of antigen testing in early diagnosis is particularly prominent in this epidemic. By realizing early screening of infections through this test kit, doctors can administer precise medication based on test results: timely use of anti-influenza drugs for influenza patients, and focused respiratory support for children infected with RSV, avoiding the abuse of antibacterial drugs. At the same time, a clear diagnosis can help patients take quarantine measures as early as possible, reducing the risk of transmission within families and communities.
From a public health perspective, fast and accurate test data can also provide real-time epidemic dynamics for health authorities, helping to judge virus prevalence trends, scientifically allocate medical resources, and reduce overall prevention and control costs. This is highly aligned with the Malaysian health authorities’ prevention and control strategy of "early detection and early handling."
A Choice Adapted to Market Prevention and Control Needs
As an important market for respiratory pathogen testing in Southeast Asia, Malaysia’s demand for multi-target test products is continuously rising. Data from 2024 shows that the global respiratory pathogen test reagent market maintains rapid growth, and Southeast Asia — where Malaysia is located — has become one of the fastest-growing regions due to its high population density and climate suitable for virus transmission. Chinese enterprises have gained international recognition for their technological accumulation in this field; previously, products such as COVID-19 test kits have obtained certification and entered the Malaysian market, providing support for local epidemic prevention and control.
The newly launched 5-in-1 antigen combo test kit not only inherits the advantages of Chinese test products — "speed, accuracy, and convenience" — but also optimizes detection targets based on the current situation of multi-virus prevalence in Malaysia. Its internationally recognized certification and mature supply chain system ensure that the product can quickly respond to local needs, providing strong support for scenarios such as school reopening, community prevention and control, and hospital diagnosis and treatment.
Conclusion: Precise Testing Builds a Solid Prevention and Control Line
Although the current influenza epidemic in Malaysia has not seen a sharp rise in the severe case rate, the prevalence of co-circulating viruses still requires high vigilance. As Malaysia’s health authorities emphasized, "collective responsibility and precise prevention and control are the keys to combating infectious diseases." With its multi-target detection capability, easy operation, and early diagnosis value, the COVID-19/RSV/ADV/Flu A&B Antigen Combo Rapid Test Kit has become an important tool for building a precise prevention and control system.
In this battle against viruses, precise testing is the first line of defense. With the promotion and application of such combo test products, Malaysia will be able to more efficiently track virus transmission routes, implement classified management and control, build a solid protection barrier for public health, and help calm the epidemic and restore normal life order as soon as possible.
